Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Core Insights - The company is optimistic about the progress of the new Biogen, particularly in the context of the Alzheimer's drug launch, LEQEMBI [1] Group 1: Product Development - The recent approval for subcutaneous maintenance of LEQEMBI is seen as a significant advancement for patient treatment options [1] - The company has initiated a rolling submission for subcutaneous initiation, which is expected to enhance patient accessibility to the treatment [1] - The potential for patients to use an autoinjector at home represents a shift towards more convenient treatment options, while still allowing the choice of infusion center visits [1]